HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors by Gallo, Alessandra et al.








HNF1฀ is a sensitive and specific novel marker for yolk sac tumor: a tissue
microarray analysis of 601 testicular germ cell tumors
Gallo, Alessandra ; Fankhauser, Christian ; Hermanns, Thomas ; Beyer, Jörg ; Christiansen, Ailsa ;
Moch, Holger ; Bode, Peter Karl
Abstract: Hepatocyte Nuclear Factor 1 beta (HNF1฀) is a transcription factor which plays an important
role during early organogenesis, especially of the pancreato-biliary and urogenital tract. Furthermore,
HNF1฀ is an established marker in the differential diagnosis of ovarian cancer and shows a distinct nuclear
expression in the clear cell carcinoma subtype. Recently, it has been described in yolk sac tumor, which
represents a common component in many non-seminomatous germ cell tumors. Due to its broad histologic
diversity, the diagnosis may be challenging and additional tools are very helpful in the workup of germ cell
tumors. Immunohistochemistry was used to study HNF1฀ expression in a tissue microarray (TMA) of 601
testicular germ cell tumors including seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma,
teratoma, germ cell neoplasia in situ (GCNIS), and normal tissue. The expression pattern was compared
to glypican 3 (GPC3) and ฀-fetoprotein (AFP), two markers currently in use for the detection of yolk
sac tumor. HNF1฀ showed a distinct nuclear staining in comparison to the cytoplasmic pattern of GPC3
and AFP. The sensitivity and specificity of HNF1฀ were 85.4% and 96.5%, of GPC3 83.3% and 90.7%,
of AFP 62.5% and 97.7%. We conclude that HNF1฀ allows a reliable distinction of yolk sac tumor from
other germ cell tumor components. Therefore, we propose HNF1฀ as a novel and robust marker in the
immunohistochemical workup of testicular germ cell tumors.
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Hepatocyte Nuclear Factor 1 beta (HNF1β) is a transcription factor which plays an important role during early 
organogenesis, especially of the pancreato-biliary and urogenital tract. Furthermore, HNF1β is an 
established marker in the differential diagnosis of ovarian cancer and shows a distinct nuclear expression in 
the clear cell carcinoma subtype. Recently, it has been described in yolk sac tumor, which represents a 
common component in many non-seminomatous germ cell tumors. Due to its broad histologic diversity, the 
diagnosis may be challenging and additional tools are very helpful in the workup of germ cell tumors. 
Immunohistochemistry was used to study HNF1β expression in a tissue microarray (TMA) of 601 testicular 
germ cell tumors including seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma, 
germ cell neoplasia in situ (GCNIS) and normal tissue. The expression pattern was compared to glypican 3 
(GPC3) and α-fetoprotein (AFP), two markers currently in use for the detection of yolk sac tumor. HNF1β 
showed a distinct nuclear staining in comparison to the cytoplasmic pattern of GPC3 and AFP. The 
sensitivity and specificity of HNF1β were 85.4 % and 96.5 %, of GPC3 83.3 % and 90.7 %, of AFP 62.5 % 
and 97.7 %. We conclude that HNF1β allows a reliable distinction of yolk sac tumor from other germ cell 
tumor components. Therefore, we propose HNF1β as a novel and robust marker in the 
immunohistochemical workup of testicular germ cell tumors. 
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Introduction 
Testicular germ cell tumors (GCT) represent only 1% of all cancers in males. They are however, the most 
common neoplasms of the testis. Their predominance in young men in the fertile and productive phase of life 
makes them an important entity (1). WHO 2016 classification divided TGCT into two major groups according 
to whether they derived from germ cell neoplasia in situ (postpubertal germ cell tumors) or not (spermatocytic 
tumors, prepubertal-type teratoma and yolk sac tumor). Testicular GCT derived from germ cell neoplasia in 
situ (GCNIS) can further be classified into two main categories which have an impact on the clinical 
management: Seminomas and non-seminomatous GCT. The latter are subdivided into undifferentiated 
components (embryonal carcinoma) and into components with embryonal differentiation (teratoma) and 
extra-embryonal differentiation (choriocarcinoma and yolk sac tumor). Due to this heterogeneity, morphologic 
overlap between the different subtypes can be a challenge in daily practice. Nonetheless, the accurate 
histopathological diagnosis is critical for further patient management (2). To enhance diagnostic accuracy, 
immunohistochemistry can serve as a valuable tool. 
Among the mentioned GCT subtypes, yolk sac tumor (YST) shows the broadest morphological spectrum 
with more than ten described architectural patterns (3). This diversity highlights the need for reliable markers. 
Current diagnostic algorithms recommend α-fetoprotein (AFP) and glypican 3 (GPC3) as YST markers, 
although their sensitivity and specificity are not perfect. Recently, Rougemont and colleagues reported on 
Hepatocyte Nuclear Factor 1 beta (HNF1β) expression in 45 testicular and ovarian GCT and concluded that 
it is a sensitive and reliable marker for the detection of YST (4). 
The aim of our study was to assess HNF1β expression in a large cohort of over 600 testicular GCT and to 
compare its sensitivity and specificity to the established markers AFP and GPC3.  
 
Materials and methods 
Patient selection 
Paraffin blocks from 601 testicular GCT (period from 1990 to 2014, mean patient age of 36 years) were 
retrieved from the archives of Institute of Pathology and Molecular Pathology, University Hospital Zurich, 
Switzerland. Two pathologists with special expertise in testicular pathology (AG, PKB) re-evaluated the 
slides and classified the tumors according to the 2016 WHO Classification. The resulting cohort consisted of 
392 pure seminomas (65.2 %), 147 non-seminomatous GCT (23.6 %), 58 mixed seminomatous and non-
seminomatous GCT (9.7 %) and 4 spermatocytic tumors (0.7 %). 
 
Tissue Microarray 
A tissue microarray (TMA) was created as previously described (5). Two tissue cores with a diameter of 0.6 
mm were taken from every tumor. In mixed GCT every subtype was punched twice separately in order to 
reflect the tumor heterogeneity. In summary, the TMA contained the following components: 450 seminomas, 
123 embryonal carcinomas, 48 yolk sac tumors, 42 teratomas, 8 choriocarcinomas, 4 spermatocytic tumors 
and 24 precursor lesions (GCNIS) from adjacent testicular tissue. In addition, non-neoplastic testicular tissue 
was included from 35 patients who underwent diagnostic procedures due to infertility. During processing 17 
tissue cores were lost. In total, 1451 testicular tissue cores were analyzed. 
 
Whole slides 
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In addition to the TMA, 15 whole slides of GCT with at least 20 % of YST component were selected in order 
to analyze the immunohistochemical staining in different growth patterns. Nine cases were primary tumors, 
six cases metastases. The blocks chosen covered the most common growth patterns: microcystic-reticular, 
macrocystic, solid, glandular and hepatoid. If a case showed different growth patterns, each pattern was 
analyzed separately. Details are summarized in table 2. 
 
Histology and Immunohistochemistry 
Three μ thick sections of TMA blocks were mounted on glass slides (SuperFrost Plus; Menzel, 
Braunschweig, Germany), deparaffinized, rehydrated and stained with hematoxylin and eosin using standard 
protocols.  
We investigated the expression of HNF1β using a polyclonal antibody (SIGMA Chemical Company, dilution 
1:200). The immunostaining was performed with the Leica Bond III 255 Stainer. Positive control tissues were 
normal kidney, liver, lung, prostate and brain tissue. The staining pattern observed was nuclear. 
GPC3 expression was investigated by using the antibody clone 1G12 (DCS Immuno Line, dilution 1:100). 
Paraffin embedded cell blocks of several cell lines were used as positive controls (Myeloid cell line, Marimo; 
human ovary adenocarcinoma: Ovcar-3; Human melanoma cell line: SK-Mel-30; Human hepatocellular 
carcinoma: HepG2; human colon adenocarcinoma: SW480). The staining pattern observed was both 
membranous and cytoplasmic.  
For AFP immunostaining, a polyclonal antibody (DAKO, dilution 1:1000) was used. Fetal liver tissue was 
used as a positive control. The positive tissues often showed a granular cytoplasmic staining pattern. 
Sometimes a strong unspecific background staining, especially in necrotic and cystic areas was noted, as is 
characteristic for a secreted protein. This background reaction was not considered positive. 
Both stainings (GPC3 and AFP) were performed on the Ventana Stainer platform in combination with 
OptiView DAB Kit. The microarray spots were digitalized and evaluated by two pathologists (AG, PKB) using 
imaging software (NanoZoomer by Hamamatsu). Tissue cores were dichotomized into positive vs negative 
cases. All cores with > 5 % of positive cells (according to the above mentioned staining patterns) were 
counted as positive. If one core of the punched tumor component was positive and the other one negative, 




Due to a moderate to strong nuclear staining the expression of HNF1β was easy to evaluate. Overall, the 
YST tumor component showed a homogeneous staining pattern in 31/48 cases (both cores positive) and a 
heterogeneous staining pattern in 10/48 cases (only one core positive). Of the 48 cases assessed, seven 
were found to be negative.  
In the other non-seminomatous components a weak to moderate HNF1β expression was observed in 24/346  
cases. All seminomas, spermatocytic tumors, GCNIS and non-neoplastic testicular tissue samples were 
negative. 
HNF1β exhibited a sensitivity of 85.4 % (the 95%CI is 0.7162 to 0.9345) and a specificity of 96.5 % (the 
95%CI is 0.9476 to 0.9770). 
 
GPC3 Immunohistochemistry 
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In contrast to HNF1β, the staining pattern of GPC3 was membranous and/or cytoplasmic. Due to a weak 
background staining, only a moderate to strong signal was considered positive. A more or less 
homogeneous pattern was observed in 32/48 YST cases (both cores positive), whereas a heterogeneous 
pattern was seen in 8/48 cases (only one core positive). Of the 48 YST cases investigated, 8 were negative. 
Among non YST cases GPC3 expression was weak to moderate. It was most commonly detected in 
embryonal carcinoma (57/123 cases), 1/42 teratoma and 6/8 choriocarcinoma. Interestingly, 27/450 
seminoma and 16/25 GCNIS showed a faint homogenous staining pattern which was interpreted as 
unspecific background and finally considered negative. 
GPC3 showed a sensitivity of 83.3 % (the 95%CI is 0.6923 to 0.9203) and a specificity of 90.7 % (the 95%CI 
is 0.8818 to 0.9269). 
 
AFP Immunohistochemistry 
The third marker AFP had a typically granular cytoplasmic expression. In our study, it showed a 
homogeneous staining pattern in 20/48 cases of YST (both cores positive) and a heterogeneous staining 
pattern in 10/48 cases (only one core positive). Of the YST investigated cases, 18/48 were negative. AFP 
was positive in 11/123 embryonal carcinoma, in 3/42 teratoma and in 2/8 choriocarcinoma. Spermatocytic 
tumors, seminoma and GCNIS were negative. 
The sensitivity of AFP was 62.5 % (the 95%CI is 0.4733 to 0.7567) and the specificity was 97.7 % (the 
95%CI is 0.9616 to 0.9862). 
 
All results are summarized in Table 1 and Figure 1. 
 
Whole slides 
A semi-quantitative evaluation was performed: homogenous expression (> 50 % positive cells), 
heterogenous expression (5-50 % positive cells), scattered single cells (< 5 % positive cells). 
Strong and homogenous HNF1β expression was detected in all cases, except in solid YST in which a 
heterogenous expression pattern was observed.  In contrast, GPC3 and AFP showed a much more 
heterogenous staining pattern, sometimes only with scattered positive cells. In one case (lymph node 
metastasis) GPC3 and AFP were negative. The results are summarized in Table 2 and Figure 2. 
 
Discussion 
In this study of more than 600 testicular GCT, we analyzed HNF1β expression in testicular YST and non 
YST components and compared it to the commonly used and recommended markers AFP and GPC3 (6). 
We found that HNF1β had a comparable sensitivity relative to GPC3 (85.4 % versus 83.3 %) and a 
comparable specificity relative to AFP (96.5 % versus 97.7 %). However, HNF1β had a higher sensitivity 
than AFP (85.4 % versus 62.5 %) and a slightly higher specificity than GPC3 (96.5 % versus 90.7 %). 
 
Postpubertal testicular GCT can show a striking heterogeneity consisting of different components, e.g. 
seminoma, embryonal carcinoma, YST, choriocarcinoma and teratoma. The correct diagnosis and 
quantification of the different components has an important influence on further therapeutic management (2). 
The morphologic overlap between the distinct tumor subtypes can represent a significant diagnostic 
challenge (7, 8). This is further compounded by the fact that YST alone is known for its broad morphology. 
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The current WHO classification lists eleven different growth patterns: microcystic/reticular, myxomatous, 
macrocystic, solid, glandular/alveolar, endodermal sinus / perivascular, hepatoid, papillary, sarcomatoid / 
spindle cell, parietal and polyvescicular vitelline. All of them may occur in combination and can imitate other 
GCT (3). In particular, the solid and glandular pattern can be difficult to differentiate from embryonal 
carcinoma, which behaves in a more aggressive fashion and may need a more intensive treatment (9). 
Therefore, immunohistochemistry is recommended in difficult cases (6).  
 
Currently, AFP and GPC3 are the best characterized YST markers (10). During development, AFP is 
physiologically secreted by the yolk sac (11). Up to now, AFP remains the gold standard marker for YST and 
correlates with corresponding serum levels. Hence, it is an integral part of clinical workup and follow-up in 
GCT patients (12). AFP however, may not be the optimal marker as relevant serum AFP isoforms can also 
be detected in patients with non-neoplastic and neoplastic liver disease (13). AFP immunohistochemistry 
shows a heterogeneous pattern with a granular cytoplasmic staining (10). When compared to AFP, GPC3 
has been shown to be a more sensitive marker for YST (14, 15), although the expression pattern was also 
found to be heterogeneous. Interestingly, similar to that observed for AFP, GPC3 can also be expressed in 
liver neoplasms (16), and in other non-testicular tumors (17-19). 
 
HNF1β is a nuclear protein that is a member of the homeodomain-containing superfamily of transcription 
factors (20). Its expression was previously observed in fetal liver, pancreas, stomach, lung and kidney, 
indicating a possible role in the development of these organs (21, 22). HNF1β mutations can cause renal 
cysts and maturity-onset diabetes of the young (MODY5) (23). Rebouissou and colleagues suggested that 
HNF1β germline mutations predispose to renal tumors and proposed a role for HNF1β as a tumor 
suppressor in chromophobe renal cell carcinoma (24). Moreover, a possible association between HNF1β 
polymorphisms and susceptibility to prostate cancer is described (25). Kato et al reported an overexpression 
of HNF1β not only in clear cell carcinoma of the ovary but also in endometriosis. In both entities, the authors 
observed a reduction of apoptosis suggesting a potential role for HNF1β in inhibition of apoptotic pathway 
activation (26). In pathological practice, HNF1β is the current marker used for detection of clear cell 
carcinoma of the ovary (27, 28). Interestingly, the somatic subtype of YST can arise in clear cell carcinoma of 
the ovary, both of which express HNF1β (29). Based on this finding, Rougemont and Tille investigated 
HNF1β expression in 45 testicular and ovarian YST. In their study, the sensitivity was 100% and the 
specificity 80%. In summary, and in accordance with data presented here, they concluded that HNF1β 
represents a reliable YST marker (4). 
 
In our study, we concentrated on the analysis of HNF1β, AFP and GPC3 expression in testicular GCT to 
establish specificity and sensitivity values for each marker. We chose a TMA based approach which allowed 
us to investigate more than 600 tumors. HNF1β expression was found in 85.4 % of YST, compared to 
83.3 % for GPC3 and 62.5 % for AFP. Specificity values were 96.5 % (HNF1β), 90.7 % (GPC3) and 97.7 % 
(AFP). HNF1β expression was also detected in 16 cases of teratoma, 7 cases of embryonal carcinoma and 
in one case of choriocarcinoma (Table 1 and Figure 1). The HNF1β-positivity in teratomas was only seen in 
mature and not in immature elements, particularly in glands with intestinal differentiation which is in line with 
previous findings by Rougemont and Tille (4). In the cases of HNF1β positive embryonal carcinoma, only a 
few cells were positive. Interestingly, GPC3 immunostaining was also positive in these cases, suggesting 
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small foci of previously undetected YST. The only HNF1β positive choriocarcinoma case exhibited a weak 
nuclear staining in a background cytoplasmic pattern which was in line with the results of Rougemont and 
Tille who observed the identical pattern in their cases of choriocarcinomas (4).  
 
In contrast to HNF1β, GPC3 also stained 46.3 % of embryonal carcinomas and 75% (6/8) of 
choriocarcinomas. In these cases, the intensity of staining was generally weak to moderate in comparison to 
YST, which exhibited a moderate to strong GPC3 staining. Hence, GPC3 does not reach the specificity of 
HNF1β or AFP. Similar results were also described by other groups (15, 30). AFP showed a slightly higher 
specificity than HNF1β in our study (97.7 % versus 96.5 %) but the sensitivity was inferior (62.5 % versus 
85.4 %). In addition, HNF1β expression is nuclear which makes it easier to evaluate than the cytoplasmic 
and membranous staining pattern seen in AFP and GPC3 immunohistochemistry. This facilitates the 
detection especially of very small foci of YST. 
 
Remarkably, Rougemont and Tille described a sensitivity of 100 % for HNF1β in their study but the 
immunostainings were conducted on whole slides. The reason for our lower sensitivity value might be due to 
the TMA approach, which may underestimate the real prevalence of positive cases because of sampling 
errors and tumor heterogeneity. Thus, we studied 15 additional GCT with a considerable percentage of YST 
on whole slides to analyze HNF1β heterogeneity in different YST growth patterns. In fact, in all cases 
(primary tumors and metastases) we could demonstrate a strong and quite homogeneous HNF1β 
expression except in solid YST, in which less than 50 % tumor cells were positive. In contrast, AFP and GPC 
more often showed a heterogeneous pattern. However, the number of examined standard blocks is small 
and we could not analyze all reported YST growth patterns. Therefore, our study remains somewhat 
weakened by the TMA approach although it allowed a larger number of cases to be examined. 
 
There exist some more limitations. Firstly, we mainly investigated untreated tumors. After chemotherapy, 
morphology can be much more difficult to interpret due to regressive changes and the persistence of unusual 
growth patterns (31, 32). Moreover, protein expression can change after treatment. For instance, CD30 
expression can be lost in embryonal carcinoma in a post-chemotherapeutic setting (33). Secondly, our TMA 
cohort consisted of primary tumors. Sometimes testicular GCT primarily manifest or relapse with metastasis. 
In this setting, correct diagnosis may be challenging because of morphologic overlap to other tumor entities 
like carcinomas (34). Thirdly, somatic-type malignancies arising in GCT were not included in our study. Thus, 
further investigations of HNF1β expression are needed to further elucidate the diagnostic utility of HNF1β in 
the three scenarios described. 
 
In summary, we investigated HNF1β expression in more than 600 testicular GCT. Compared to the 
commonly used YST markers AFP and GPC3, HNF1β immunohistochemistry has a higher sensitivity than 
AFP and a higher specificity than GPC3. Furthermore, the nuclear expression pattern makes it easy to 
evaluate. Therefore, we conclude that HNF1β is a reliable marker in the diagnosis of YST and recommend 
that it be added to immunohistochemical panels in the differential diagnosis of testicular GCT. 
 
Disclosure/Conflict of Interest: None to declare. 
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Legends 
 
Figure 1. Histology (column 1) and expression patterns of GPC3 (column 2), AFP (column 3) and HNF1β 
(column 4) in non-seminomatous testicular tumors: A. Yolk Sac Tumor (YST). B. Embryonal Carcinoma 
(EC). C. Teratoma (intestinal differentiation). D. Choriocarcinoma (CC). 
GPC3 with a negative example of YST (A2). EC shows a weak cytoplasmic staining (B2). Teratoma is 
negative (C2). CC with scattered weakly stained syncytiotrophoblasts (D2). 
AFP with strong and diffuse positivity in YST (A3). EC (B3), Teratoma (C3) and CC (D3) are negative. 
HNF1β shows a strong nuclear expression in YST (A4). EC with no nuclear staining (B4). Glandular 
proliferations with intestinal differentiation in teratoma exhibit a striking nuclear staining (C4). CC with a 
diffuse cytoplasmic staining (D4).  
All images 200x magnification. 
 
Figure 2. HNF1β expression in different YST growth patterns. A. Strongly positive YST component 
intermixed with negative embryonal carcinoma. B. Macrocystic pattern. C. Hepatoid. D. Solid. E. Glandular. 
F. Microcystic/reticular. All images 100x magnification. 
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